使用PSMA配体99mTc-MIP-1404的SPECT/CT对前列腺癌患者进行全身原发分期
本研究回顾性分析93例组织学确诊的前列腺癌患者,在治疗前使用99mTc-MIP-1404 SPECT/CT进行全身原发分期。结果显示该显像对前列腺癌诊断准确率高、观察者间变异低,并可检测淋巴结和骨转移;TUprostate与Gleason评分和PSA血清浓度相关,能以中等准确度预测淋巴结或骨转移的发生。
要点
- 99mTc-MIP-1404 SPECT/CT在前列腺癌诊断中准确率高、观察者间一致性高。
- TUprostate与Gleason评分≥8分及PSA≥10 ng/mL显著相关。
- TUprostate>26预测淋巴结或骨转移的敏感度为82%、特异度为76%。
核心结论
- MIP-1404 SPECT/CT对前列腺癌诊断准确率高、观察者间变异低,可在相当比例未经治疗的患者中检出淋巴结和骨转移。
- TUprostate与Gleason评分和PSA血清浓度相关,在原发分期时能以中等准确度预测淋巴结或骨转移的发生。
研究设计与样本
- 回顾性检索2013年4月至2017年5月临床数据库,纳入93例组织学确诊、治疗前接受99mTc-MIP-1404 SPECT/CT全身原发分期的前列腺癌患者。
- 注射706±72 MBq 99mTc-MIP-1404后3至4小时采集全身平面及下腹部和胸部SPECT/CT图像,由2名经验丰富的核医学医师视觉分析。
- 评估原发肿瘤和转移灶检出的观察者间一致性,并计算前列腺内反映总肿瘤负荷的变量TUprostate。
- 52例(56%)患者有后续治疗随访报告,中位随访18个月。
主要发现
- 93例中90例(97%)检测到前列腺摄取高于背景,作为组织学诊断前列腺癌的对应表现。
- 16例患者检出48个淋巴结转移,9例患者检出29个骨转移;另有3例患者有播散性骨转移,未发现远处器官转移。
- 观察者间一致性:总体扫描结果97%,原发肿瘤97%,淋巴结转移97%,骨转移99%。
- 有随访资料的52例患者中5例(10%)出现前列腺癌复发。
- TUprostate在Gleason评分≥8分患者中显著高于Gleason评分≤7分患者,在PSA血清水平≥10 ng/mL患者中显著高于PSA≤10 ng/mL患者。
关键数值与推荐
- 原发肿瘤TUprostate>26预测淋巴结或骨转移:敏感度82%,特异度76%。
- 观察者间一致性:总体扫描结果97%、原发肿瘤97%、淋巴结转移97%、骨转移99%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) is a novel ligand binding to prostate-specific membrane antigen suitable for SPECT. There are, as yet, no data concerning its use in whole-body primary staging and its interobserver variability in patients with prostate cancer (PC) prior to therapy. METHODS: A search of our clinical database from April 2013 to May 2017 yielded 93 patients with histologically confirmed cancer in whom Tc-MIP-1404 SPECT/CT had been performed for primary whole-body staging before therapy. Whole-body planar and SPECT/CT images of the lower abdomen and thorax had been obtained 3 to 4 hours postinjection of 706 ± 72 MBq Tc-MIP-1404. Images were visually analyzed for extent and location of abnormal uptake by 2 experienced nuclear physicians. Interobserver agreement for detection of primary tumor and metastatic lesions was assessed. In addition, SUVs of prostate-specific membrane antigen-positive regions of the prostate were determined in all patients, and from these, a variable reflecting total tumor load in the prostate gland was calculated (TUprostate). Follow-up reports of subsequent therapeutic interventions were available in 52 (56%) of all patients with a median follow-up of 18 months. RESULTS: In 90 (97%) of 93 patients, prostate uptake above background was detected as correlate of the histologically diagnosed PC. Forty-eight lymph node and 29 bone metastases were detected in 16 and 9 patients, respectively. In addition, 3 patients had disseminated bone metastases. No distant organ metastases were found. Interobserver agreement was high for the overall scan result (97%), as well as for the detection of the primary tumor (97%), of lymph node metastases (97%), and of bone metastases (99%). Recurrence of PC occurred in 5 patients in whom follow-up was available (10%). TUprostate was significantly higher in patients with Gleason scores of 8 or greater compared with patients with Gleason scores of 7 or less and at prostate-specific antigen (PSA) serum levels of 10 ng/mL or greater compared with PSA serum levels of 10 ng/mL or less. TUprostate of greater than 26 in the primary tumor predicted the occurrence of lymph node or bone metastases with a sensitivity of 82% and specificity of 76%. CONCLUSIONS: MIP-1404 SPECT/CT has a high accuracy and low interobserver variability in the diagnosis of PC and allows detection of lymph node and bone metastases in a significant proportion of as yet untreated PC patients. TUprostate is correlated with Gleason score and PSA serum concentration and allows prediction of the occurrence of lymph node and bone metastases with moderate accuracy at primary staging.
引用
- Schmidkonz C, Cordes M, Beck M, et al. SPECT/CT With the PSMA Ligand 99mTc-MIP-1404 for Whole-Body Primary Staging of Patients With Prostate Cancer. Clin Nucl Med. 2018. PMID: 29401151. doi:10.1097/RLU.0000000000001991
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。